<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="205673">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411294</url>
  </required_header>
  <id_info>
    <org_study_id>ZA-01</org_study_id>
    <nct_id>NCT00411294</nct_id>
  </id_info>
  <brief_title>Ergocalciferol in Chronic Kidney Disease</brief_title>
  <official_title>The Effect of Ergocalciferol Treatment on 25-Hydroxyvitamin D Levels and Plasma Intact PTH in Patients With Chronic Kidney Disease Stage 3 and 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Louis VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Louis VA Medical Center</source>
  <brief_summary>
    <textblock>
      To examine the effect of ergocalciferol treatment on 25-hydroxyvitamin D and PTH levels in
      patients with CKD stage 3 and 4
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Longitudinal, Retrospective</time_perspective>
  </study_design_info>
  <condition>Chronic Kidney Disease</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with CKD stage 3 or 4 whose 25-hydroxyvitamin D levels are below 30 ng/ml and
             plasma intact PTH levels &gt;70 pg/ml.

        Exclusion Criteria:

          -  Patients who are on any form of active vitamin treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziyad Al-Aly, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VAMC-Saint Louis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Louis VA Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <lastchanged_date>December 11, 2006</lastchanged_date>
  <firstreceived_date>December 11, 2006</firstreceived_date>
  <keyword>ergocalciferol</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>secondary hyperparathyroidism</keyword>
  <keyword>vitamin D deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
